Final results of the UK Age trial on breast cancer screening age
by Anthony B Miller
The Lancet
Oncology: VOLUME 21,
ISSUE 9, P1125-1126, SEPTEMBER 01, 2020
In The Lancet Oncology, the findings from a 23-year
follow-up of the UK Age trial are presented by Stephen Duffy and colleagues.1
No difference in mortality from breast cancer was found between the group that
began yearly mammography screening at age 39–41 years until they entered the
National Health Service (NHS) Breast Screening Programme at age 50–52 years,
and a group that did not begin mammography screening until they entered the NHS
Breast Screening Programme (126 deaths vs 255 deaths occurring after more than
10 years of follow-up; relative rate 0·98 [95% CI 0·79–1·22]; p=0·86).
